DD-04107 is under clinical development by BCN Peptides and currently in Phase III for Pruritus. According to GlobalData, Phase III drugs for Pruritus have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how DD-04107’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DD-04107 overview

Parentide (DD-04107) is under development for the treatment of pruritus or uticaria. It is administered through cutaneous route. The drug candidate is a synthetic peptide. It acts by targeting transient receptor potential vanilloid subfamily 1 (TRPV1). It is administered through subcutaneous route and formulated as powder and solvent for solution. It is administered through cutaneous route and formulated as cream. It was under development for neuropathic pain, cancer pain, chronic inflammatory and diabetic neuropathy.

BCN Peptides overview

BCN Peptides, a subsidiary of Lipotec SA, is a contract manufacturing company that manufactures bioactive peptides for pharmaceutical and veterinary applications. The company offers the production of bulk generic peptides and custom synthesis of proprietary API peptides. It develops technologies such as solid phase synthesis, HPLC purification, lyophilization under GMP conditions, and sterile peptides for custom synthesis. BCN Peptides conducts synthetic development, analytical development, ICH stability study, IMPD and IND and CTD and DMF preparation, regulatory support, FDA and EMEA, commercial manufacturing, and analysis of pharmaceutical final products. The company operates through its manufacturing facilities in Sant Quinti de Mediona, Spain. BCN Peptides is headquartered in Barcelona, Spain.

For a complete picture of DD-04107’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.